[Registration No. 197301001753 (14809-W)]

(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

For the Twelve - Months Ended 31 December 2021

(The figures have not been audited)

	Current C 3 months 31-Dec-21 RM'000		Cummulative 12 months 31-Dec-21 RM'000	
Revenue	227,535	206,882	694,657	669,049
Other operating income	1,519	20	5,198	7,293
Fair value gain/(loss) on biological assets	(2,643)	(3,534)	4,501	201
Fair value gain on investment property	1,000	-	1,000	-
Fair value loss on other financial assets	-	(731)	-	(731)
Depreciation and amortisation	(9,097)	(8,875)	(31,883)	(28,027)
Operating expenses	(169,509)	(170,825)	(527,334)	(568,479)
Finance income	486	143	1,264	531
Finance cost	(1,411)	(1,520)	(4,973)	(2,068)
Share of profit after tax of associates	18,554	12,540	68,022	34,436
Profit before taxation	66,434	34,100	210,452	112,205
Tax expense	(9,552)	8,123	(35,670)	(9,055)
Net profit for the period	56,882	42,223	174,782	103,150
Attributable to:				
Owners of the Company	52,967	39,591	164,266	97,982
Non-controlling interests	3,915 56,882	2,632 42,223	10,516 174,782	5,168 103,150
	30,882	42,223	174,762	103,130
Earnings per share attributable to owners of the Company (sen):				
Basic	8.92	6.67	27.66	16.50
Diluted	8.92	6.67	27.66	16.50

The condensed consolidated statements of comprehensive income should be read in conjunction with the audited financial statements for the year ended 31 December 2020 and the accompanying notes attached to the interim financial statements.

[Registration No. 197301001753 (14809-W)]

(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION As At 31 December 2021

(The figures have not been audited)

	Note	As at 31-Dec-21 RM'000 Unaudited	As at 31-Dec-20 RM'000 Audited
Non-current assets		2112121212	
Property, plant and equipment		319,610	328,030
Investment property		61,000	60,000
Investment in associates		524,143	474,063
Right of use assets		438,758	445,920
Biological assets		635	474
		1,344,146	1,308,487
Current assets			
Inventories		10,528	6,067
Biological assets		9,303	4,803
Receivables		72,686	73,385
Tax recoverable		1,526	119
Deposits, bank and cash balances		148,351	79,123
		242,394	163,497
Total assets		1,586,540	1,471,984
Equity Share capital Retained earnings Equity attributable to Owners of the Company Non-controlling interests Total equity		197,946 1,051,948 1,249,894 44,012 1,293,906	197,946 947,474 1,145,420 37,154 1,182,574
Non current liabilities			
Deferred tax liabilities		74,583	73,709
Lease liabilities		16,191	16,293
Borrowings	24	116,250	131,250
Ç		207,024	221,252
Current liabilities Payables		68,127	47,441
Tax payables		2,384	5,411
Borrowings	24	15,000	15,000
Lease liabilities		99	306
		85,610	68,158
Total liabilities		292,634	289,410
Total equity and liabilities		1,586,540	1,471,984
Net assets per share attributable to Owners of the Company (RM)		2.18	1.99

Note: Total numbers of share capital is 593,837,985 units.

The condensed consolidated statements of financial position should be read in conjunction with the audited financial statements for the year ended 31 December 2020 and the accompanying notes attached to the interim financial statements.

[Registration No. 197301001753 (14809-W)]

(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

For the Twelve - Months Ended 31 December 2021

(The figures have not been audited)

	Attributable to owners of the Company			on-controlling interests	Total equity
	Share capital RM'000	Retained earnings RM'000	Total RM'000	RM'000	RM'000
Balance at 1 January 2021	197,946	947,474	1,145,420	37,154	1,182,574
Total comprehensive income	-	164,266	164,266	10,516	174,782
Share of other comprehensive income of associate Dividends for the year ended	-	(408)	(408)	-	(408)
- 31 December 2020	-	(29,692)	(29,692)	-	(29,692)
- 31 December 2021	-	(29,692)	(29,692)	-	(29,692)
Dividend paid to non-controlling interest	-	-	-	(3,658)	(3,658)
Balance at 31 December 2021	197,946	1,051,948	1,249,894	44,012	1,293,906
Balance at 1 January 2020	197,946	873,338	1,071,284	35,365	1,106,649
Total comprehensive income	-	97,982	97,982	5,168	103,150
Share of other comprehensive income of associate Dividends for the year ended	-	(3,062)	(3,062)	-	(3,062)
- 31 December 2019	-	(8,907)	(8,907)	-	(8,907)
- 31 December 2020	-	(11,877)	(11,877)	-	(11,877)
Dividend paid to non-controlling interest	-	-	-	(3,379)	(3,379)
Balance at 31 December 2020	197,946	947,474	1,145,420	37,154	1,182,574

The condensed consolidated statements of changes in equity should be read in conjunction with the audited financial statements for the year ended 31 December 2020 and the accompanying explanatory notes attached to the interim financial statements.

[Registration No. 197301001753 (14809-W)]

(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

For the Twelve - Months Ended 31 December 2021

(The figures have not been audited)

Name	(The ligures have not been addited)	Year-to-date	ended	
Profit before tax		31-Dec-21	31-Dec-20 RM'000	
Adjustments for: Depreciation and amortisation Gain on disposal of property, plant and equipment Loss on disposal of property, plant and equipment Property, plant and equipment written off City, plant and equipment City, purchase City, purchase City, plant and equipment City, purchase City, purchase City, purchase City, plant and equipment City, purchase City, purchase City, purchase City, plant and equipment City, purchase City, purchase City, plant and equipment City, purchase City, purchas	Operating activities			
Depreciation and amortisation		210,452	112,205	
Gain on disposal of property, plant and equipment - 19 Loss on disposal of property, plant and equipment - 19 Property, plant and equipment written off - 2 Other receivables written off - 22 (Reversal)/Impairment loss of trade receivables (30) 361 Fair value loss on other financial assets - 731 Fair value gain on biological assets (4,501) (201) Fair value gain on investment property (1,000) - Share of profit after tax of associates (68,022) (34,436) Gain on sales of biological assets (161) (434) Finance income (1,264) (531) Finance cost 4,973 2,071 Operating profit before working capital 172,061 107,836 Changes in working capital: (4,461) (596) - receivables, deposits and prepayments 730 (3,041) - payables 20,686 14,573 Cash from operations 189,016 118,772 Finance cost paid (4,973) (2,071				
Loss on disposal of property, plant and equipment Property, plant and equipment written off			28,027	
Property, plant and equipment written off - 2 Other receivables written off - 22 (Reversal)/Impairment loss of trade receivables (30) 361 Fair value loss on other financial assets - 731 Fair value gain on biological assets (4,501) (201) Fair value gain on investment property (1,000) - Share of profit after tax of associates (68,022) (34,436) Gain on sales of biological assets (161) (434) Finance income (1,264) (531) Finance cost 4,973 2,071 Operating profit before working capital 172,061 107,836 Changes in working capital: - - - inventories (4,461) (596) - receivables, deposits and prepayments 730 (3,041) - payables 20,686 14,573 Cash from operations 189,016 118,772 Finance cost paid (4,973) (2,071) Finance income received 1,264 531 Tax refunded		(269)	-	
Other receivables written off (Reversal)/Impairment loss of trade receivables - 22 (Reversal)/Impairment loss of trade receivables - 731 561 731 731 731 731 731 731 731 731 731 73		-		
(Reversal)/Impairment loss of trade receivables (30) 361 Fair value loss on other financial assets - 731 Fair value gain on biological assets (4,501) (201) Fair value gain on investment property (1,000) - Share of profit after tax of associates (68,022) (34,436) Gain on sales of biological assets (161) (434) Finance income (1,264) (531) Finance income (1,264) (531) Finance cost 4,973 2,071 Operating profit before working capital 172,061 107,836 Changes in working capital: - (4,461) (596) - receivables, deposits and prepayments 730 (3,041) - payables 20,686 14,573 Cash from operations 189,016 118,772 Finance income received 1,264 531 Tax refunded 5 6,917 Tax paid (39,235) (17,353) Net cash flow from operating activities 146,077 106,796 <td c<="" td=""><td></td><td>-</td><td></td></td>	<td></td> <td>-</td> <td></td>		-	
Fair value loss on other financial assets Fair value gain on biological assets Fair value gain on biological assets Fair value gain on biological assets Fair value gain on investment property Fair value gain on biological assets Finance of profit after tax of associates Gain on sales of biological assets Finance income Finance cost Finance cost Changes in working capital Finance income received Finance ost paid Finance cost paid Finance cost paid Finance income received Finance inc		-		
Fair value gain on biological assets (4,501) (201) Fair value gain on investment property (1,000) - Share of profit after tax of associates (68,022) (34,436) Gain on sales of biological assets (161) (434) Finance income (1,264) (531) Finance cost 4,973 2,071 Operating profit before working capital 172,061 107,836 Changes in working capital: - (4,461) (596) - receivables, deposits and prepayments 730 (3,041) - payables 20,686 14,573 (2,071) Cash from operations 189,016 118,772 (3,041) (4,973) (2,071) Finance cost paid (4,973) (2,071) (4,973) (2,071) (4,973) (2,071) Finance income received 1,264 531 5 6,917 Tax refunded 5 6,917 (39,235) (17,353) Net cash flow from operating activities 146,077 106,796 Investing activities	· · · ·	(30)		
Fair value gain on investment property Share of profit after tax of associates (68,022) (34,436) Gain on sales of biological assets (161) (434) Finance income (1,264) (531) Finance cost (4,973 (2,071) Operating profit before working capital Changes in working capital: - inventories - receivables, deposits and prepayments - payables - receivables, deposits and prepayments - payables Cash from operations Tax from operations Finance cost paid (4,973) Finance cost paid (4,973) Finance income received 1,264 Tax refunded 5 Tax paid Net cash flow from operating activities Property, plant and equipment - purchase - proceed from disposal Dividend from associate companies Biological assets - purchase - purchase - purchase - purchase - proceed from sales - proceed from sales - proceed from sales - (29,897) Net advances to related parties - (73)		-		
Share of profit after tax of associates (68,022) (34,436) Gain on sales of biological assets (161) (434) Finance income (1,264) (531) Finance cost 4,973 2,071 Operating profit before working capital 172,061 107,836 Changes in working capital: - (4,461) (596) - receivables, deposits and prepayments 730 (3,041) - payables 20,686 14,573 Cash from operations 189,016 118,772 Finance cost paid (4,973) (2,071) Finance income received 1,264 531 Tax refunded 5 6,917 Tax paid (39,235) (17,353) Net cash flow from operating activities 146,077 106,796 Investing activities Property, plant and equipment - (950) - proceed from disposal 269 93 Dividend from associate companies 17,534 16,793 Biological assets - (950) - proceed from sales - (950) - proceed fr			(201)	
Gain on sales of biological assets (161) (434) Finance income (1,264) (531) Finance cost 4,973 2,071 Operating profit before working capital 172,061 107,836 Changes in working capital: - receivables, deposits and prepayments 730 (3,041) - receivables, deposits and prepayments 730 (3,041) - payables 20,686 14,573 Cash from operations 189,016 118,772 Finance cost paid (4,973) (2,071) Finance income received 1,264 531 Tax refunded 5 6,917 Tax paid (39,235) (17,353) Net cash flow from operating activities 146,077 106,796 Investing activities Property, plant and equipment - (950) - proceed from disposal 269 93 Dividend from associate companies 17,534 16,793 Biological assets - (950) - proceed from sales - (950)			-	
Finance income (1,264) (531) Finance cost 4,973 2,071 Operating profit before working capital 172,061 107,836 Changes in working capital: - inventories (4,461) (596) - receivables, deposits and prepayments 730 (3,041) - payables 20,686 14,573 Cash from operations 189,016 118,772 Finance cost paid (4,973) (2,071) Finance income received 1,264 531 Tax refunded 5 6,917 Tax paid (39,235) (17,353) Net cash flow from operating activities 146,077 106,796 Investing activities 269 93 Dividend from disposal 269 93 Dividend from associate companies 17,534 16,793 Biological assets - (950) - purchase - (950) - proceed from sales - (29,897) Net advances to related parties - (29,897)			·	
Finance cost 4,973 2,071 Operating profit before working capital 172,061 107,836 Changes in working capital: - inventories (4,461) (596) - receivables, deposits and prepayments 730 (3,041) - payables 20,686 14,573 Cash from operations 189,016 118,772 Finance cost paid (4,973) (2,071) Finance income received 1,264 531 Tax refunded 5 6,917 Tax paid (39,235) (17,353) Net cash flow from operating activities 146,077 106,796 Investing activities 146,077 106,796 Investing activities 146,077 106,796 Investing activities 16,301) (32,427) - proceed from disposal 269 93 Dividend from associate companies 17,534 16,793 Biological assets - (950) - proceed from sales - (950) - proceed from sales - (29,897)				
Operating profit before working capital 172,061 107,836 Changes in working capital:			· · ·	
Changes in working capital: (4,461) (596) - receivables, deposits and prepayments 730 (3,041) - payables 20,686 14,573 Cash from operations 189,016 118,772 Finance cost paid (4,973) (2,071) Finance income received 1,264 531 Tax refunded 5 6,917 Tax paid (39,235) (17,353) Net cash flow from operating activities 146,077 106,796 Investing activities Property, plant and equipment - (16,301) (32,427) - purchase (16,301) (32,427) - - proceed from disposal 269 93 Dividend from associate companies 17,534 16,793 Biological assets - (950) - purchase - (950) - proceed from sales - (950) - purchase of right-of-use assets - (29,897) Net advances to related parties - (73)	_			
- inventories (4,461) (596) - receivables, deposits and prepayments 730 (3,041) - payables 20,686 14,573 Cash from operations 189,016 118,772 Finance cost paid (4,973) (2,071) Finance income received 1,264 531 Tax refunded 5 6,917 Tax paid (39,235) (17,353) Net cash flow from operating activities 146,077 106,796 Investing activities Property, plant and equipment (16,301) (32,427) - purchase (16,301) (32,427) - proceed from disposal 269 93 Dividend from associate companies 17,534 16,793 Biological assets - (950) - proceed from sales - (950) - proceed from sales - (29,897) Net advances to related parties - (73)		172,061	107,836	
- receivables, deposits and prepayments 730 (3,041) - payables 20,686 14,573 Cash from operations 189,016 118,772 Finance cost paid (4,973) (2,071) Finance income received 1,264 531 Tax refunded 5 6,917 Tax paid (39,235) (17,353) Net cash flow from operating activities 146,077 106,796 Investing activities Property, plant and equipment (16,301) (32,427) - proceed from disposal 269 93 Dividend from associate companies 17,534 16,793 Biological assets - (950) - proceed from sales - (950) - proceed from sales - (29,897) Net advances to related parties - (73)			/	
- payables 20,686 14,573 Cash from operations 189,016 118,772 Finance cost paid (4,973) (2,071) Finance income received 1,264 531 Tax refunded 5 6,917 Tax paid (39,235) (17,353) Net cash flow from operating activities 146,077 106,796 Investing activities Property, plant and equipment - (16,301) (32,427) - purchase (16,301) (32,427) - - proceed from disposal 269 93 Dividend from associate companies 17,534 16,793 Biological assets - (950) - purchase - (950) - proceed from sales - (29,897) Net advances to related parties - (73)			· · ·	
Cash from operations 189,016 118,772 Finance cost paid (4,973) (2,071) Finance income received 1,264 531 Tax refunded 5 6,917 Tax paid (39,235) (17,353) Net cash flow from operating activities 146,077 106,796 Investing activities Property, plant and equipment (16,301) (32,427) - purchase (16,301) (32,427) - proceed from disposal 269 93 Dividend from associate companies 17,534 16,793 Biological assets - (950) - purchase - (950) - proceed from sales - 1,601 Purchase of right-of-use assets - (29,897) Net advances to related parties - (73)			• • • •	
Finance cost paid (4,973) (2,071) Finance income received 1,264 531 Tax refunded 5 6,917 Tax paid (39,235) (17,353) Net cash flow from operating activities 146,077 106,796 Investing activities Property, plant and equipment (16,301) (32,427) - purchase (16,301) (32,427) - proceed from disposal 269 93 Dividend from associate companies 17,534 16,793 Biological assets - (950) - proceed from sales - (950) - purchase of right-of-use assets - (29,897) Net advances to related parties - (73)				
Finance income received 1,264 531 Tax refunded 5 6,917 Tax paid (39,235) (17,353) Net cash flow from operating activities 146,077 106,796 Investing activities Property, plant and equipment - purchase (16,301) (32,427) - proceed from disposal 269 93 Dividend from associate companies 17,534 16,793 Biological assets - (950) - purchase - (950) - proceed from sales - 1,601 Purchase of right-of-use assets - (29,897) Net advances to related parties - (73)	·			
Tax refunded 5 6,917 Tax paid (39,235) (17,353) Net cash flow from operating activities 146,077 106,796 Investing activities Property, plant and equipment (16,301) (32,427) - purchase (16,301) (32,427) - proceed from disposal 269 93 Dividend from associate companies 17,534 16,793 Biological assets - (950) - purchase - (950) - proceed from sales - 1,601 Purchase of right-of-use assets - (29,897) Net advances to related parties - (73)	•	• • •	• • • •	
Tax paid (39,235) (17,353) Net cash flow from operating activities 146,077 106,796 Investing activities Property, plant and equipment - purchase (16,301) (32,427) - proceed from disposal 269 93 Dividend from associate companies Biological assets - purchase - (950) 17,534 16,793 - proceed from sales - purchase of right-of-use assets - (29,897) - (29,897) Net advances to related parties - (73)				
Investing activities 146,077 106,796 Property, plant and equipment - purchase - proceed from disposal Dividend from associate companies Biological assets - purchase - (950) - proceed from sales - 1,601 (16,301) (32,427) (32,42				
Investing activities				
Property, plant and equipment (16,301) (32,427) - purchase (16,301) (32,427) - proceed from disposal 269 93 Dividend from associate companies 17,534 16,793 Biological assets - (950) - purchase - (950) - proceed from sales - 1,601 Purchase of right-of-use assets - (29,897) Net advances to related parties - (73)	Net cash flow from operating activities	146,077	106,796	
- purchase (16,301) (32,427) - proceed from disposal 269 93 Dividend from associate companies 17,534 16,793 Biological assets - (950) - purchase - 1,601 Purchase of right-of-use assets - (29,897) Net advances to related parties - (73)	Investing activities			
- proceed from disposal 269 93 Dividend from associate companies 17,534 16,793 Biological assets - (950) - purchase - 1,601 Purchase of right-of-use assets - (29,897) Net advances to related parties - (73)	Property, plant and equipment			
Dividend from associate companies 17,534 16,793 Biological assets - (950) - purchase - 1,601 Purchase of right-of-use assets - (29,897) Net advances to related parties - (73)	•			
Biological assets - (950) - purchase - (950) - proceed from sales - 1,601 Purchase of right-of-use assets - (29,897) Net advances to related parties - (73)	·			
- purchase - (950) - proceed from sales - 1,601 Purchase of right-of-use assets - (29,897) Net advances to related parties - (73)	•	17,534	16,793	
- proceed from sales - 1,601 Purchase of right-of-use assets - (29,897) Net advances to related parties - (73)	Biological assets			
Purchase of right-of-use assets - (29,897) Net advances to related parties - (73)	- purchase	-	(950)	
Net advances to related parties (73)	- proceed from sales	-	1,601	
	Purchase of right-of-use assets	-	(29,897)	
Net cash flow from/(used in) investing activities 1,502 (44,860)	Net advances to related parties	-	(73)	
	Net cash flow from/(used in) investing activities	1,502	(44,860)	

[Registration No. 197301001753 (14809-W)]

(Incorporated in Malaysia)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW (cont'd.)

For the Twelve - Months Ended 31 December 2021

(The figures have not been audited)

(The figures have not been addited)	Year-to-date	ended
	31-Dec-21 RM'000	31-Dec-20 RM'000 Audited
Financing activities		
Dividends paid to:		
-Owners of the Company	(59,384)	(20,785)
-Non-controlling interest	(3,658)	(3,378)
Drawdown of short term borrowing	-	26,500
Repayment of short term borrowing	-	(26,500)
Repayment of term loan	(15,000)	(3,750)
Payment for the principal portion of lease liabilities	(309)	(296)
Net advances from associates	-	224
Net advances from related companies	-	(233)
Net cash used in financing activities	(78,351)	(28,218)
Net increase in cash and cash equivalents Cash and cash equivalents	69,228	33,718
-at start of the year	79,123	45,405
-at end of the year	148,351	79,123

The condensed consolidated statements of cash flow should be read in conjunction with the audited financial statements for the year ended 31 December 2020 and the accompanying notes attached to the interim financial statements.

[Registration No. 197301001753 (14809 - W)] (Incorporated in Malaysia)

1. BASIS OF PREPARATION AND ACCOUNTING POLICIES

The interim financial statements are unaudited and have been prepared in accordance with the requirements of MFRS 134: Interim Financial Reporting and paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.

The interim financial statements should be read in conjunction with the Group's audited financial statements for the year ended 31 December 2020. These explanatory notes attached to the interim financial statements provide an explanation of events and transactions that are significant to an understanding of the changes in the financial position and performance of the Group since the year ended 31 December 2020.

The accounting policies applied in this interim financial report is the same as those applied in the Group's consolidated financial statements as at and for the year ended 31 December 2020.

The interim financial statements of the Group for the financial year ended 31 December 2021 was prepared in accordance with the Malaysian Financial Reporting Standards ("MFRS") Framework. At the date of authorisation of these interim financial statements, the following Standards and amendments to Standards have been issued by the Malaysian Accounting Standards Board ("MASB") but are not yet effective to the Group's current financial year.

Effective for financial period beginning on or after 1 April 2021

Amendments to MFRS 16 COVID-19 Related rent concessions beyond 30 June

2021

Effective for financial period beginning on or after 1 January 2022

Amendments to MFRS 3 Reference to the conceptual framework

Amendments to MFRS 116 Property, plant and equipment - proceeds before

intended use

Amendments to MFRS 137 Onerous contract - cost of fulfilling a contract

Annual improvement to MFRSs 2018 - 2020

Effective for financial period beginning on or after 1 January 2023

MFRS 17 and Amendments to Insurance contracts

MFRS 17

Amendments to MFRS 101 Classification of liabilities as current or non-current

and Disclosure of accounting policies

Amendments to MFRS 108 Definition of accounting estimates

Amendments to MFRS 112 Deferred tax related to assets and liabilities arising

from a single transaction

[Registration No. 197301001753 (14809 - W)] (Incorporated in Malaysia)

Effective date has been deferred and yet to be announced

Amendments to MFRS 10 and MFRS 128

Sale or contribution of assets between an investor and its associate or joint venture

2. COMMENTS ABOUT SEASONAL OR CYCLICAL FACTORS

The Group's plantations business is affected by seasonal crop production, weather condition, fluctuating commodity prices, labour supplies and the impact of COVID-19 pandemic.

3. UNUSUAL ITEMS DUE TO THEIR NATURE, SIZE OR INCIDENCE

There were no unusual items affecting assets, liabilities, equity, net income or cash flows that are unusual because of their nature, size or incidence in the current quarter and financial year ended 31 December 2021.

4. SIGNIFICANT ESTIMATES AND CHANGES IN ESTIMATES

There were no material changes in estimates of amounts that have any material effect in the current quarter and financial year ended 31 December 2021.

5. DISCLOSURE ON QUALIFICATION ON AUDIT REPORT

The audit report of the Group's financial statements for the financial year ended 31 December 2020 was not qualified.

6. ISSUANCE, CANCELLATIONS, REPURCHASES, RESALE AND REPAYMENTS OR DEBTS AND EQUITY SECURITIES

There were no issuances, cancellations, repurchases, resale and repayments of debt and equity securities in the current quarter and financial year ended 31 December 2021.

7. DIVIDENDS PAID

Dividend paid is as follow:-

	3 month	s ended	12 months ended		
	31.12.2021 RM'000	31.12.2020 RM'000	31.12.2021 RM'000	31.12.2020 RM'000	
Interim dividend	29,692 ¹	11,877 ²	29,692 ¹	11,877 ²	
Interim dividend	-	-	-	8,9074	
Final dividend	-	-	29,692 ³	-	
Total	29,692	11,877	59,384	20,784	

Note:

1 An interim single tier dividend of five (5.00) sen per share for the financial year ended 31 December 2021 was paid on 23 December 2021.

[Registration No. 197301001753 (14809 - W)] (Incorporated in Malaysia)

- 2 An interim single tier dividend of two (2.00) sen per share for the financial year ended 31 December 2020 was paid on 22 December 2020.
- 3 A final single tier dividend of five (5.00) sen per share for the financial year ended 31 December 2020 was paid on 30 June 2021.
- 4 A second interim single tier dividend of one point five (1.50) sen per share for the financial year ended 31 December 2019 was paid on 14 July 2020.

8. SEGMENTAL REPORTING

No segmental reporting has been prepared as the group activities are predominantly in plantation activity, which is mainly carried out in Malaysia.

9. PROPERTY, PLANT AND EQUIPMENT

The Group upon the adoption of MFRS has elected to use the cost model from previous revaluation policy by using the last revaluation as deemed cost.

10. INVESTMENT PROPERTY

The Group owns a piece of land at Bandar Indera Mahkota, Kuantan, Pahang. The asset was classified under investment property based on a fair value model under MFRS 140.

11. SUBSEQUENT MATERIAL EVENTS

There was no subsequent material event after the balance sheet date.

12. CHANGES IN THE COMPOSITION OF THE GROUP

There were no other changes in the composition of the Group during the current quarter and financial year ended 31 December 2021.

13. CONTINGENT LIABILITIES OR CONTINGENT ASSETS

There were no contingent liabilities or contingent assets as at 31 December 2021.

14. REVIEW OF PERFORMANCE

	3 months ended			12 months ended		
Financial Information	31.12.2021 RM'000	31.12.2020 RM'000	Variance %	31.12.2021 RM'000	31.12.2020 RM'000	Variance %
Revenue	227,535	206,882	10	694,657	669,049	4
Profit before tax	66,434	34,100	95	210,452	112,205	88
Profit after tax	56,882	42,223	35	174,782	103,150	69

[Registration No. 197301001753 (14809 - W)] (Incorporated in Malaysia)

	3 months ended			12 months ended		
Production	31.12.2021 Mt	31.12.2020 Mt	Variance %	31.12.2021 Mt	31.12.2020 Mt	Variance %
FFB	85,079	84,082	1	289,985	316,710	(8)
СРО	16,284	16,048	1	55,094	59,678	(8)
PK	3,926	4,142	(5)	14,038	15,606	(10)
FFB processed by mills	123,540	129,340	(4)	435,520	499,030	(13)

	3 months ended			3 months ended 12 months ended		
Yield per hectare	31.12.2021 Mt/ha	31.12.2020 Mt/ha	Variance %	31.12.2021 Mt/ha	31.12.2020 Mt/ha	Variance %
FFB yield	4.99	5.24	(5)	17.01	19.74	(14)
CPO yield	0.95	1.00	(5)	3.23	3.72	(13)

	3 months ended			12 months ended		
Average Price	31.12.2021 RM/Mt	31.12.2020 RM/Mt	Variance %	31.12.2021 RM/Mt	31.12.2020 RM/Mt	Variance %
Average CPO price/mt	5,115	3,140	63	4,321	2,719	59
Average PK price/mt	3,806	2,074	84	2,874	1,640	75

Current Quarter vs Preceding Corresponding Quarter

For the current quarter ended 31 December 2021, the Group posted a higher revenue, profit before tax and profit after tax when compared to the corresponding quarter of preceding year, mainly due to:-

- (a) Higher average CPO and PK prices per metric tonne by 63% and 84% respectively. The average CPO price per metric tonne was RM5,115 (2020: RM3,140) and the average PK price per metric tonne was RM3,806 (2020: RM2,074);
- (b) Higher share of profit from associated companies by RM6.01 million (48%);
- (c) Fair value gain recognised on investment property by RM1 million (100%); and
- (d) Increase in other operating income by RM1.5 million (749%).

Current Year-to-date vs Preceding Year-to-date

For the financial year ended 31 December 2021, the Group posted higher revenue, profit before tax and profit after tax when compared to the preceding financial year, mainly due to:-

- (a) Higher average CPO and PK prices per metric tonne by 59% and 75% respectively. The average CPO price per metric tonne was RM4,321 (2020: RM2,719) and the average PK price per metric tonne was RM2,874 (2020: RM1,640);
- (b) Higher share of profit from associated companies by RM33.59 million (98%);
- (c) Higher fair value gain on biological asset by RM4.30 million (2139%); and
- (d) Fair value gain recognised on investment property of RM1 million (100%).

[Registration No. 197301001753 (14809 - W)] (Incorporated in Malaysia)

15. COMPARISON WITH PRECEDING QUARTER'S RESULTS

		3 months ended				
Financial Information	31.12.2021 RM'000	30.9.2021 RM'000	Variance RM'000	Variance %		
Revenue	227,535	193,654	33,881	17		
Profit before tax	66,434	66,680	(246)	(0.3)		
Profit after tax	56,882	54,920	1,962	4		

	3 months ended					
Production	31.12.2021 Mt	30.9.2021 Mt	Variance Mt	Variance %		
FFB production	85,079	77,033	8,046	10		
CPO production	16,284	14,600	1,684	12		
PK production	3,926	3,698	228	6		
FFB processed by mills	123,540	116,368	7,172	6		

	3 months ended			
Yield per hectare	31.12.2021 Mt/ha	30.9.2021 Mt/ha	Variance Mt/ha	Variance %
FFB yield	4.99	4.61	0.38	8
CPO yield	0.95	0.88	0.07	8

		3 months ended			
Average Price	31.12.2021 RM/Mt	30.09.2021 RM/Mt	Variance RM/Mt	Variance %	
Average CPO price/mt	5,115	4,409	706	16	
Average PK price/mt	3,806	2,534	1,272	50	

For the current quarter ended 31 December 2021, the Group posted higher revenue as compared to the preceding quarter, mainly due to:-

- (a) Higher FFB production by 8,046 metric tonne (10%);
- (b) Higher average prices of CPO and PK by 16% and 50% respectively; and
- (c) Higher FFB processed by the Group's palm oil mills by 7,172 metric tonne (6%).

16. GAIN OR LOSS ON DISPOSAL OF QUOTED OR UNQUOTED INVESTMENT OR PROPERTIES

There were no gain or loss on disposal of quoted or unquoted investment or properties for the current quarter and financial year ended 31 December 2021.

17. FOREIGN EXCHANGE GAIN OR LOSS

The Group does not have any foreign exchange gain or loss for the current quarter and financial year ended 31 December 2021.

[Registration No. 197301001753 (14809 - W)] (Incorporated in Malaysia)

18. GAIN OR LOSS ON DERIVATIVES

The Group does not have any gain or loss on derivatives for the current quarter and financial year ended 31 December 2021.

19. PROSPECTS

FFB production is forecasted to be stable in year 2022 and the Group's financial result for year 2022 is expected to sustain as per performance of 2021.

However the Group's performance for the upcoming financial year would continue to be challenging due to the COVID-19 pandemic, rising operation costs, higher wages and labor shortages.

20. CAPITAL COMMITMENTS

The amount of capital commitments not provided for in the financial statements is as follow:-

	As at 31.12.2021 RM'000	As at 31.12.2020 RM'000
Property, plant and equipment	6,115	8,430
Oil palm estates development	8,344	9,486
Acquisition of land	7,550	8,950
Total	22,009	26,866

21. VARIANCE FROM PROFIT FORECAST/PROFIT GUARANTEE

Not applicable as there was no profit forecast nor profit guarantee published.

22. TAX EXPENSE

	3 months ended		12 months ended	
	31.12.2021 RM'000	31.12.2020 RM'000	31.12.2021 RM'000	31.12.2020 RM'000
Tax Expenses				
Current year	8,703	6,760	35,531	22,480
Under/(Over) accrued in previous year	(25)	(1,406)	(735)	52
<u>Deferred tax</u>				
Current year	3,580	3,525	3,580	3,525
Under/(Over) accrued in previous year	(2,706)	(17,002)	(2,706)	(17,002)
Total	9,552	(8,123)	35,670	9,055

The effective tax rate of the Group for the financial year ended 31 December 2021 and 31 December 2020 is calculated at Malaysian statutory tax rate of 24% based on the assessable profit for the year.

[Registration No. 197301001753 (14809 - W)] (Incorporated in Malaysia)

23. STATUS OF CORPORATE PROPOSALS

There were no corporate proposals for the current quarter and financial year ended 31 December 2021.

24. BORROWING

Particular of the Group's borrowing is as follow:-

	31.12.2021 RM'000	31.12.2020 RM'000
Non-current liability		
Term loan (secured)	116,250	131,250
Current liabilities		
Term loan (secured)	15,000	15,000
Total	131,250	146,250

25. OFF BALANCE SHEET FINANCIAL INSTRUMENTS

During the current quarter and financial year ended 31 December 2021, the Group did not enter into any contract involving off balance sheet instruments.

26. STATUS OF THE MATERIAL LITIGATIONS

There was no material litigation of the Group during the current quarter and financial year ended 31 December 2021.

27. STATUS ON THE JOINT VENTURE PROJECTS

The status on the joint venture projects for the development of oil palm plantation between Far East Holdings Berhad and Rangkaian Delima Sdn. Bhd.

(a) Far East Delima Plantations Sdn. Bhd. ("FEDP")

FEDP had recorded an unaudited profit before tax of RM12.98 million for the financial year ended 31 December 2021.

(b) F.E.Rangkaian Sdn. Bhd. ("FERSB")

FERSB had recorded an unaudited profit before tax of RM11.21 million for the financial year ended 31 December 2021.

28. INVESTMENT IN FUTURE PRELUDE SDN. BHD. ("FPSB")

FPSB recorded an unaudited profit before tax of RM31.80 million for the financial year ended 31 December 2021.

[Registration No. 197301001753 (14809 - W)] (Incorporated in Malaysia)

29. DIVIDENDS

(a) Paid in financial year ended 31 December 2021

(i) Current quarter for the financial year ended 31 December 2021

On 25 November 2021, the Company had announced an interim single tier dividend of five (5.00) sen per share in respect of the financial year ended 31 December 2021. The payment was made on 23 December 2021 to the shareholders whose names appear in the Record of Depositors of the Company at the close of business on 10 December 2021.

The final dividend for the financial year ended 31 December 2021 would be announced at a later date.

(ii) Dividend for the financial year ended 31 December 2020

On 28 April 2021, the Company had announced payment for a final single tier dividend of five (5.00) sen per share for the financial year ended 31 December 2020. The dividend was approved at the Annual General Meeting on 9 June 2021 and the payment date was on 30 June 2021.

(b) Paid in financial year ended 31 December 2020

(i) Current quarter for the financial year ended 31 December 2020

On 26 November 2020, the Company had announced an interim single tier dividend of two (2.00) sen per share in respect of the financial year ended 31 December 2020. The payment was made on 22 December 2020 to the shareholders whose names appear in Record of Depositors of the Company at the close of business on 14 December 2020.

(ii) Dividend for the financial year ended 31 December 2019

On 29 April 2020, the Company had announced the payment for second interim single tier dividend of one point five (1.50) sen per share for the financial year ended 31 December 2019 and the payment date was on 14 July 2020.

[Registration No. 197301001753 (14809 - W)] (Incorporated in Malaysia)

30. EARNINGS PER SHARE ("EPS")

(a) Basic EPS

Basic EPS is calculated by dividing the profit for the period attributable to ordinary equity holders of the owners of the Company by the weighted average number of ordinary shares in issue during the period:-

	3 months ended		12 months ended	
	31.12.2021	31.12.2020	31.12.2021	31.12.2020
Profit attributable to equity holder of the owners of the Company (RM'000)	52,967	39,591	164,266	97,892
Weighted average number of ordinary shares in issue ('000)	593,838	593,838	593,838	593,838
Basic EPS (sen)	8.92	6.67	27.66	16.50

(b) Diluted EPS

There was no diluting factor to earnings per share for the current quarter.

31. AUTHORISED FOR ISSUE

The financial statements were authorised for issue on 23 February 2022 by the Board of Directors in accordance with the resolution of the Directors.